NewcelX Ltd. NCEL
Annual
Quarterly
No annual revenue total was found in NewcelX Ltd.'s SEC filings.
NewcelX Ltd. (NCEL) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$2.8 million.
Revenue
—
Net income
$-8.30M
-15.3% vs prior year
Operating cash flow
$-2.77M
-159.5% vs prior year
Free cash flow
$-2.77M
-158.8% vs prior year
EPS
$2.16
-11.1% vs prior year
Dividend per share
None
Shares outstanding
4.80M
+51.8% vs prior year
Net cash
$-19,419
FY 2020
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NCEL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Zurich
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1783036
- Former names
- NLS Pharmaceutics Ltd. (until Oct 30, 2025)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$2.6M | -$2.1M | -$3.0M | -$15.5M | -$11.9M |
| Net income | -$8.3M | -$7.2M | -$3.3M | -$16.5M | -$11.9M |
| Diluted EPS | $2.16 | $2.43 | $1.13 | -$33.52 | — |
| Operating cash flow | -$2.8M | -$1.1M | -$3.4M | -$13.9M | -$14.9M |
| Free cash flow | -$2.8M | -$1.1M | — | — | -$15.0M |
| Total assets | $11.4M | $903,000 | $1.8M | $9.3M | $5.8M |
| Total liabilities | $4.2M | $8.9M | $10.7M | $6.0M | $5.2M |
| Stockholders' equity | $7.2M | -$8.0M | -$1.2M | $111,000 | $542,388 |
| Cash and investments | $2.2M | $650,000 | $1.1M | $8.9M | $5.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 4, 2026 | Nov 4, 2026 |
| 6-K | Current report (foreign issuer) | Sep 18, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Aug 3, 2026 | Aug 3, 2026 |
| 6-K | Current report (foreign issuer) | Jul 31, 2026 | Jul 31, 2026 |
| 6-K | Current report (foreign issuer) | Jul 15, 2026 | Jul 15, 2026 |
| 6-K | Current report (foreign issuer) | Jul 8, 2026 | Jul 8, 2026 |
All 417 NewcelX Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.